Cellectra™ Human CD14 NanoSort Microbeads, Research grade

ユーザーレビュー
製品番号/仕様
価格
Availability
数量
MBS-S026-2ml
$513.00
In Stock - Delivery in 1-2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Product
    Size
    Amount
    Cellectra™ Human CD14 NanoSort Microbeads, Research grade
    2 mL
    For 10⁹ total cells
  • Product Description

    Cellectra™ Human CD14 NanoSort Microbeads, Research grade are dextran-coated superparamagnetic iron oxide nanoparticles of which the surface is conjugated with recombinant monoclonal antibodies specific to human CD14 (Isotype: mouse IgG2a). They are especially designed for positive selection of CD14+ cells.
    Cellectra™ Human CD14 NanoSort Microbeads, Research grade are produced under sterile manufacturing conditions (ISO 5), and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.

  • Application

    Cellectra™ Human CD14 NanoSort Microbeads, Research grade are designed for the positive selection of monocytes and macrophages from fresh or frozen human peripheral blood mononuclear cells (PBMCs). CD14, a glycosylphosphatidylinositol (GPI)-anchored membrane protein, is predominantly expressed on the surface of human monocytes and macrophages. The magnetic Microbeads are conjugated with monoclonal antibodies targeting human CD14 protein, enabling CD14+ cells to be labeled with the specific antibodies and magnetic particles, and separated using the separation columns and magnets.

  • Storage

    For long term storage, the product should be stored in liquid state at -20°C or below Stability upon receipt: 1. Stable for 24 months at -20 °C or below; 2. Stable for 9 months at 2–8 °C under sterile conditions.

    Please protect from light and avoid repeated freeze-thaw cycles.

  • Sterility

    Negative

  • Endotoxin

    Less than 2 EU per mL by the LAL method / rFC method.

  • Mycoplasma

    Negative

  • Important Note

    This product is for research use only and not intended for therapeutic or in vivo diagnostic use.

  • Formulation

    Supplied in PBS buffer containing EDTA, rHSA and Poloxamer 188.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • Application Data

     CD14 APPLICATION DATA

    Superior Cell Separation Performance (Comparison with Company M)
    Separation performance was evaluated using samples containing 1×10⁷ human PBMCs, processed with CD14 microbeads from Acro, Company M at recommended dosages. Positive and negative fractions were collected, and 1×10⁶ cells from each fraction were immunostained with PE-conjugated anti-human CD14 antibody and 7-AAD, followed by flow cytometric analysis. Data indicated that Acro microbeads achieved a final purity of 98.01% (baseline: 22.03%), with a target cell residue of only 0.40% in the negative fraction. These findings validate outstanding separation performance, confirming an optimal balance of purity and recovery relative to Company M benchmarks.

  •  CD14 APPLICATION DATA

    Comparison of Cell Separation Performances
    Isolation efficacy was validated using samples containing 1×10⁷ human PBMCs processed with the recommended dosage of Cellectra™ Human CD14 NanoSort Microbeads, in parallel with Company M. The comparative analysis demonstrated that Acro NanoSort Microbeads is consistent with Company M. Furthermore, high post-isolation cell viability was preserved, confirming suitability for sensitive downstream applications.

  •  CD14 APPLICATION DATA

    Cell Separation Performances after Freeze-Thawing and Accelerated Aging at 37℃
    Freeze-thaw stability was verified by subjecting the microbeads to 2–3 cycles prior to separation testing. Comparative analysis against the standard batch confirmed that purity and cell recovery were maintained at baseline specifications, demonstrating robust stability. To ensure prolonged shelf life, storage at -20°C or below is recommended upon receipt (however, repeated freeze-thaw cycles are not advised for routine operational use).
    Accelerated aging studies were conducted at 37°C to evaluate long-term stability profiles. Following 4 and 7-day incubation periods, the microbeads sustained high purity and cell recovery performance during PBMC separation. These data substantiate product stability and validate the established shelf-life specifications.

ユーザーレビュー
コメントを投稿

最新の進展

 
医薬品開発の進捗
  • 英語名:

    Monocyte differentiation antigen CD14

  • カテゴリ:

  • 市販の医薬品数:

    0 詳細

  • 治験医薬品数:

    3 詳細

  • 最新の開発ステージ:

    Phase 2 Clinical

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー